FOR PLUS PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of FOR PLUS PHARMA is 3.4% (moderate). The 2025 annual accounts show equity of €99,809 and a net result of €82,647. Equity is shrinking by about 27% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 38% of 13,582 sector peers (NACE 46, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
13%
According to the 2025 annual accounts of FOR PLUS PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
No directors read yet: 0 of 5 Gazette acts processed.